APLS Q4 2018 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11,542+0.0% YoY

Gross Profit

$11,542100.0% margin

Operating Income

-$37M-322275.2% margin

Net Income

-$36M-315881.1% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$204M

Total Liabilities

$43M

Stockholders' Equity

$161M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11,542	$11,542	+0.0%
Gross Profit	$11,542	$11,542	+0.0%
Operating Income	-$37M	-$18M	-106.7%
Net Income	-$36M	-$18M	-99.7%